Dual GIP/GLP-1 receptor agonists
Engineering one molecule to engage two incretin receptors — and what head-to-head data showed.
A dual agonist is a single molecule designed to activate both the GLP-1 and GIP receptors. The rationale is that the two incretins act through overlapping but non-identical mechanisms, so engaging both might exceed what either achieves alone. Tirzepatide, approved in 2022, was the first to reach clinical use and marked a genuine step-change in the field.
Published trial data support the rationale. In a head-to-head comparison reported in 2025, tirzepatide produced greater weight reduction than semaglutide 2.4 mg — roughly 20% versus 14% at 72 weeks — and reviews of the class consistently report greater reductions in body weight and glycaemic indices for dual agonism than for GLP-1 agonism alone.
Whether the advantage comes from GIP's distinct signalling, from the pharmacology of the combined molecule, or both, is still being worked out — see GIP and its receptor. The logical extension is Triple agonists: GLP-1, GIP, and glucagon. Described here as research; not medical advice.
Related articles
- MetabolicGLP-1 receptor agonistsHow GLP-1 works, and why molecules mimicking it became central to metabolic research.
- MetabolicGIP and its receptorThe other incretin hormone — long overshadowed by GLP-1, now central to combination approaches.
- MetabolicTriple agonists: GLP-1, GIP, and glucagonAdding glucagon receptor activity to incretin agonism — using a hormone long considered the opposition.
- MetabolicCardiovascular and renal findings in incretin researchWhy outcome trials — not surrogate markers — reshaped how incretin science is understood.
- MethodsClinical trial phasesWhat each stage of clinical testing is actually designed to answer.
- MetabolicThe incretin effectThe observation that started incretin science: glucose taken by mouth triggers far more insulin than the same glucose given intravenously.